Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Hoffmann-La Roche
Arnon P Kater; John F Seymour; Peter Hillmen; Barbara Eichhorst; Anton W Langerak; Carolyn Owen; Maria Verdugo; Jenny Wu; Elizabeth A Punnoose; Yanwen Jiang; Jue Wang; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Thomas J Kipps